Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : How To Write Covered Calls - An Ongoing Real Case Study! -- Ignore unavailable to you. Want to Upgrade?

To: dazzled who wrote (9561)	2/3/1999 8:12:00 AM
From: Casaubon	Respond to of 14162

all potential drugs get an advisory committee hearing. The FDA will give a reccommendation based on the data collected from the clinical trials. All the news has been positive, so far, so there is little reason to believe the drug will not pass review. As far as time line goes, all I know is fast track status means the drug MUST be reviewed by mid april. Agouron got Viracept pushed through much faster, and I think that was because it was such a dramatic improvement over crixivan. Viracept quickly cut into crixivans market share because it is a better drug; proving Merck is not invulnerable to the little guy. Agenerase looks like it is better than both of those drugs (crixivan will lose even more market share) and with the marketing muscle of Glaxo, agenerase shouls capture good market share quickly. Vertex also has been doing much to promote the advantages of agenerase and has been getting ready to initiate sales on its own. I am not trying to sell anyone on this stock!!! I am heavily invested in this company and want to make more than my 10% annualized paper gain, which I believe I can do based on the information I learned in this forum. Just as Herm posted his plays on ROST early on, I will keep people informed of the progress I make, because it seems fun! I am going to try and snowball my gains by using the premium money to purchase my stock options, and thus increase my covered writing ability.

To: dazzled who wrote (9561)	2/3/1999 1:09:00 PM
From: Casaubon	Read Replies (1) \| Respond to of 14162

I was curious if some people with more experience could comment on a couple of observations. First, yesterday Lehman Bros., a market maker for vertex, issues a downgrade from $60 to $34 12 Mo. projection. The talk on the yahoo message board was that Lehman was manipulating the market to cover their short position. Then today, somebody picks 150 contracts of the april 35 calls on VRTX. This is very unusual volume for the VRTX options, and of course very bullish! I was just wondering if someone could give me some insight to this possible market manipulation by market makers.